Scholarlink

Purpose <p>This manuscript reviews advancements in Laser Interstitial Thermal Therapy (LITT) for treating brain metastases and radiation necrosis, emphasizing its minimally invasive nature and precision in targeting deep-seated or eloquent area lesions. It analyzes studies from 2011 to 2024 to evaluate LITT’s efficacy, safety, and complications while highlighting the need for standardized clinical endpoints. Despite its potential, LITT remains a secondary treatment due to limited high-level evidence, requiring further research and multidisciplinary collaboration.</p> Methods <p>A systematic PubMed search identified 2,004 articles on LITT for brain metastases and radiation necrosis. Filtering for studies from 2011 to 2024 resulted in 60 selected articles: 4 clinical trials, 22 observational studies, 3 case reports, 2 case series, and the rest review articles. Relevant data were extracted, analyzed, and compiled for this review.</p> Results <p>LITT is primarily used for lesions unsuitable for open craniotomy, such as deep-seated or eloquent-area tumors. Literature supports its increasing neuro-oncological applications, particularly in brain metastases, gliomas, meningiomas, and radiation necrosis.</p> Conclusion <p>The evolving landscape of brain metastasis treatment underscores the importance of a multidisciplinary approach incorporating standardized reporting, advanced imaging, and molecular diagnostics. Further innovation and collaboration are needed to optimize LITT’s role in neuro-oncology and address treatment challenges in the era of personalized medicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recent advances in laser interstitial thermal therapy in the treatment of brain metastases and radiation necrosis

  • 期刊论文

  • 发表日期：

    2025年4月10日

查看全文
  • Siddharth Shah,
  • Amelia H. Alberts,
  • Sophie Tillotson,
  • Hritvik Jain,
  • Brandon Lucke-Wold

摘要

Purpose

This manuscript reviews advancements in Laser Interstitial Thermal Therapy (LITT) for treating brain metastases and radiation necrosis, emphasizing its minimally invasive nature and precision in targeting deep-seated or eloquent area lesions. It analyzes studies from 2011 to 2024 to evaluate LITT’s efficacy, safety, and complications while highlighting the need for standardized clinical endpoints. Despite its potential, LITT remains a secondary treatment due to limited high-level evidence, requiring further research and multidisciplinary collaboration.

Methods

A systematic PubMed search identified 2,004 articles on LITT for brain metastases and radiation necrosis. Filtering for studies from 2011 to 2024 resulted in 60 selected articles: 4 clinical trials, 22 observational studies, 3 case reports, 2 case series, and the rest review articles. Relevant data were extracted, analyzed, and compiled for this review.

Results

LITT is primarily used for lesions unsuitable for open craniotomy, such as deep-seated or eloquent-area tumors. Literature supports its increasing neuro-oncological applications, particularly in brain metastases, gliomas, meningiomas, and radiation necrosis.

Conclusion

The evolving landscape of brain metastasis treatment underscores the importance of a multidisciplinary approach incorporating standardized reporting, advanced imaging, and molecular diagnostics. Further innovation and collaboration are needed to optimize LITT’s role in neuro-oncology and address treatment challenges in the era of personalized medicine.